CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

J Alexandre*,1, C Brown2, D Coeffic3, N Raban4, J Pfisterer5, J Mäenpää6, H Chalchil7, B Fitzharris8, B Volgger9, I Vergote10, C Pisano11, A Ferrero12 and E Pujade-Lauraine1

1Département d’Oncologie Médicale, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, Paris, France; 2NHMRC Clinical Trials Centre, Sydney, Australia; 3Medical Oncology Department, Hôpital des Diaconesses, Paris, France; 4Department of Medical Oncology, University Hospital of Mélines, Poitiers, France; 5Department of Gynaecology, Staatstches Klinikum Solingen, Solingen, Germany; 6Department of Obstetrics and Gynecology, University of Tampere and Tampere University Hospital, Tampere, Finland; 7Department of Medicine, University of Saskatchewan, Allan Blair Cancer Centre, Regina, Saskatchewan; 8Christchurch Hospital, Christchurch, New Zealand; 9Department of Obstetrics and Gynecology, University Hospital Innsbruck, Innsbruck, Austria; 10University Hospital Leuven, Leuven Cancer Institute and Department of Gynaecological Oncology, Leuven, Belgium; 11Division of Medical Oncology, Uro-Gynaecological Department, National Cancer Institute, Naples, Italy; 12Academic Division of Gynecologic Oncology, Mauriziano Hospital, Torino, Italy

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression.

METHODS: In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin–paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression.

RESULTS: In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD vs C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66 – 1.10) and 0.84 (95% CI 0.72 – 0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81% of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment.

CONCLUSION: CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.

Keywords: ovarian cancer; CA-125; pegylated liposomal doxorubicin; carboplatin; paclitaxel; radiological
doubling as a progression criterion could alter study results or interfere with patient care by leading to overtreatment (Goonewardene et al., 2007).

The CALYPSO phase III trial that compared carboplatin–paclitaxel (C-P) with carboplatin-pegylated liposomal doxorubicin (C-PLD) as treatment for women with platinum-sensitive ROC showed improved PFS times and more favourable toxicity profile with C-PLD (Pujade-Lauraine et al., 2010). Sub-studies also demonstrated that C-PLD was associated with a lower incidence of hypersensitivity reactions compared with C-P (Joly et al., 2011) and offered a more favourable therapeutic index in patients ≥70 years old (Kurtz et al., 2011). CALYPSO is also the first large randomised trial to incorporate CA-125 (GCIG criteria) and symptomatic deterioration along with RECIST to assess for progression evaluation in women with platinum-sensitive ROC (Pujade-Lauraine et al., 2010; Lee et al., 2011). These results provide a unique opportunity to specifically address whether CA-125 should be a tumour evaluation criterion in ovarian cancer trials.

MATERIALS AND METHODS

Main eligibility criteria of GCIG CALYPSO study

As reported elsewhere, patients with cancer of the ovary or fallopian tube or extra-ovarian papillary serous carcinoma who experienced disease progression longer than 6 months after first- or second-line platinum-based chemotherapy regimen were included (Pujade-Lauraine et al., 2010). Patients had to have measurable disease according to RECIST or CA-125 assessable disease according to GCIG criteria or have a histological proven diagnosis of relapse (Therasse et al., 2000; Vergote et al., 2000).

Study design

The CALYPSO randomised phase III trial compared the combination of pegylated doxorubicin 30 mg m⁻² and carboplatin (C) AUC 5, both administered every 4 weeks for six cycles, with paclitaxel (P) 175 mg m⁻² and C AUC 5 every 3 weeks for six cycles. It was designed as a two-arm parallel non-inferiority trial to determine whether the combination of C-PLD was non-inferior to the standard regimen of C-P. The primary end point was PFS.

Patient assessment

Clinical examination and CA-125 assessment were required at baseline, then every 3 months until 2 years after treatment discontinuation, and at investigator discretion every 6 months thereafter for 5 years. Imaging (specific X-ray or CT-scan, or ultrasound or MRI) was mandatory at baseline, every 3 months while on treatment and when required during follow-up according to the centre policy and clinical indication. In the initial analysis of the entire population, the diagnosis of progression was based on the occurrence of one of the following events: (1) RECIST progression: occurrence of any new lesion or increase in measurable and/or non-measurable tumour assessed by imagery or clinically, and defined by RECIST 1.0 criteria (Therasse et al., 2000); (2) biological progression: CA-125 elevation defined by GCIG criteria (Vergote, 2000); or (3) symptomatic progression or health-status deterioration, including symptomatic deterioration attributable to disease requiring a change in therapy without objective evidence of progression. Patients with increased pre-treatment CA-125 concentrations, which later normalised, or those with pre-treatment CA-125 concentrations in the normal range needed to show evidence of a CA-125 concentration ≥2 times the upper normal limit on two occasions at least 1 week apart. Patients with increased pre-treatment CA-125 concentrations, which never normalised, needed to show evidence of CA-125 concentrations ≥2 times the nadir value on two occasions at least 1 week apart.

In the present analysis, the progression type (RECIST, CA125, or symptomatic) that occurred first was identified for each patient. Patients who progressed according to RECIST criteria within 7 days following symptomatic or CA-125 progressive disease (PD) were considered to have RECIST first PD. Similarly, patients who had symptomatic PD within 3 days following CA-125 PD without RECIST PD were considered to have symptomatic first PD. Patients for whom RECIST progression was assessed only on clinical tumour target (e.g., supra-clavicular lymph node) were considered to have symptomatic PD.

Statistical analysis

PFS was summarised by cumulative incidence curves and compared in each treatment group using multiple recurrent event Cox regression models. Hazard ratios together with 95% confidence intervals (CIs) were calculated. The time to RECIST or symptomatic progression following CA-125 elevation was evaluated by censoring patients at the date of first new treatment or date last known alive. Time to post-study treatment following first progression was evaluated by censoring patients at the date of death or date last known alive.

RESULTS

In all, 976 patients with platinum-sensitive ROC were randomised. One patient was ineligible because of no ovarian cancer and was excluded from all analyses. After a median follow-up of 22 months, 832 (85%) patients had disease progression at the time of the analysis.

Type of first progression

In the majority of patients (502 out of 832, 60%), the diagnosis of tumour progression was primarily based on a radiological worsening according to RECIST criteria (Table 1). CA-125 and/or symptomatic progression was also observed within 7 days before or after RECIST progression in 217 (44%) and 51 (10%) patients, respectively. A CA-125 progression without any evidence of RECIST or symptomatic progression was observed in 28% of patients (Table 1). In these patients, the median time from CA-125 elevation to RECIST or symptomatic progression was 2.3 months (C-P, 95% CI: 1.6–2.9) and 2.1 months (C-PLD, 95% CI: 1.4–3.0).

The cumulative incidence of the three types of disease progression is represented in Figure 1. An early progression defined as a progression occurring within 6 months following study inclusion was observed in 146 patients (Table 1). In this subset of patients compared with patients who progressed later, asymptomatic CA-125 elevation as first progression was less common as opposed to symptomatic progression.

Table 1 Type of first progression

| Type of first progression | Early progression (n = 146) | Other progressions (n = 686) | All progressions (n = 832) |
|--------------------------|----------------------------|-----------------------------|---------------------------|
| RECIST*                  | 88 (61)                    | 414 (60)                    | 502 (60)                  |
| Isolated CA-125 doubling (GCIG) | 28 (19)                | 204 (30)                    | 232 (28)                  |
| Symptomatic*            | 29 (19)                    | 54 (8)                      | 83 (10)                   |
| Unspecified/other*      | 1 (1)                      | 14 (2)                      | 15 (2)                    |

Abbreviations: GCIG = Gynaecologic Cancer Intergroup; RECIST = Response Evaluation Criteria in Solid Tumours. aIncluding patients who experienced CA-125 or clinical progression within 7 days before or after RECIST progression. bIncluding patients who experienced biological CA-125 within 3 days before or after clinical progression. cIncluding tumour progression observed during surgical procedure.
Baseline parameters associated with type of first progression

Radiological first progression was more frequent in patients with measurable disease at baseline compared with those without measurable disease at baseline (Table 2). However, even in patients without baseline measurable disease, radiological progression was the most common type of first progression. In patients who were not assessable for CA-125 at baseline, isolated CA-125 progression occurred rarely (18%). The proportions of each type of first progression were similar between the two treatment arms. Symptomatic progression was more frequent than in patients with measurable disease at baseline (17% vs 10%; Table 2). Symptomatic first progression was more frequent in patients with mucinous subtype (24%, 95% CI: 10–48) than in other cell types (12%, 95% CI: 10–14; Table 2). Tumour grade and initial tumour stage were not associated with the type of first progression (data not shown).

Table 2 Baseline parameters associated with RECIST, CA-125, or symptomatic progression (PD)

| Type of first PD       | RECIST (%) | CA-125 (%) | Symptomatic (%) |
|------------------------|------------|------------|-----------------|
| Proportion of progressions* | 60         | 28         | 10              |
| Histological subtype   |            |            |                 |
| Mucinous (n = 14)       | 50         | 21         | 14              |
| Other (n = 818)         | 61         | 29         | 12              |
| Measurable disease (TL) |            |            |                 |
| Yes (n = 551)           | 68         | 22         | 9               |
| No (n = 281)            | 46         | 39         | 12              |
| Assessable by CA-125    |            |            |                 |
| Yes (n = 587)           | 58         | 32         | 13              |
| No (n = 243)            | 65         | 18         | 9               |
| Treatment arm           |            |            |                 |
| C-P (n = 443)           | 58         | 28         | 10              |
| C-PLD (n = 389)         | 63         | 27         | 9               |

Abbreviations: C-P = carboplatin – paclitaxel; C-PLD = carboplatin–pegylated liposomal doxorubicin; PD = progressive disease; RECIST = Response Evaluation Criteria in Solid Tumours. *The totals of the values do not equal 100% because progression of unspecified type and other progressions (n = 15) were not shown, patients not progressed excluded.

Influence of type of first progression on treatment effects

In the overall study population, C-PLD was associated with improved PFS compared with C-P (11.3 vs 9.4 months, \( P = 0.005 \)). Figure 2 shows that the benefit of C-PLD over C-P was not influenced by the type of first progression. The median time from isolated CA-125 progression to RECIST progression was similar between C-P (2.3 months) and C-PLD (2.1 months).

Type of first progression and post-study therapy

The majority (81%) of patients with CA-125 or RECIST first progression received a subsequent treatment; a different treatment strategy was observed following symptomatic progression (Table 3). The median time from progression to post-study therapy was higher in patients with CA-125 first progression (60 days) than in patients with RECIST (28 days) or symptomatic progression (32 days).

DISCUSSION

Herein we report the modalities of disease progression in patients receiving second- or third-line chemotherapy in a prospective clinical trial that included follow-up with both CA-125 measurements and radiological evaluations. We observed that in the majority of patients (60%), the diagnosis of progression was based on radiological worsening (RECIST criteria). Only a third of the patients had isolated asymptomatic CA-125 progression, probably because of a micro-nodular peritoneal carcinomatosis. In these patients, the median time from isolated CA-125 doubling to radiological or symptomatic progression was 2 months. However, the curve of the cumulative incidence of type of progression suggested that isolated CA-125 progression did not occur earlier than radiological and symptomatic progression in the general population and a change in treatment strategy was delayed until this progression was observed.

Our results suggest that in patients receiving second- or third-line therapy for platinum-sensitive ROC, where physical progression is not observed first, the CT-scan subsequently detects progression of CA-125 and further clinical trials are needed to confirm these findings.
tumour progression close to that of from CA-125 measurements. This finding contrasts with previous reports in patients receiving first-line therapy (Goonewardene et al., 2007). This discrepancy is likely to be due to a higher global tumour volume in relapsing patients compared with those in the first-line treatment setting. In our study, though symptomatic first progressions were rare, they occurred more frequently in the first 6 months following treatment initiation, and were likely related to very aggressive and chemo-resistant disease.

We observed more radiological progressions in patients with measurable disease at baseline compared with those without baseline measurable disease. However, even in this latter category, nearly half of the patients experienced first radiological progression. This finding suggests that patients without measurable disease at baseline could be considered for studies that define tumour progression based only on RECIST criteria.

Patients with symptomatic progression were not treated as frequently as those with CA-125 or RECIST progression. It can be speculated that a certain number of patients at the time of symptomatic progression were considered to be unable to receive chemotherapy either because of decreased performance status related to occlusive disease or because of other causes. These findings corroborate with those of the MRC OVAR/EORTC 55955 trial (Rustin et al., 2010). In this trial of women with complete response to first-line chemotherapy, 12% of the patients with symptomatic progression in the delayed-chemotherapy arm could not receive a second-line treatment compared with only 4% of patients randomised to the arm that received chemotherapy as soon as CA-125 progression according to GCIG criteria was observed.

CA-125 measurements and CT-scans performed similarly in comparing efficacy between the two treatment arms in the CALYPSO study. This finding corroborated a previous retrospective report in the first-line chemotherapy setting for advanced ovarian cancer (Rustin et al., 2006). It is important to note that this finding cannot be generalised to all anticancer treatments because some biological therapies could interfere with CA-125 production independent of antitumour effect. On the other hand, some biological agents could delay symptomatic progression in patients with increasing CA-125. Such an effect was recently demonstrated in the CALYPSO experience with CA-125 tumour progression close to that of from CA-125 measurements. This finding contrasts with previous reports in patients receiving first-line therapy (Goonewardene et al., 2007). This discrepancy is likely to be due to a higher global tumour volume in relapsing patients compared with those in the first-line treatment setting. In our study, though symptomatic first progressions were rare, they occurred more frequently in the first 6 months following treatment initiation, and were likely related to very aggressive and chemo-resistant disease.

We observed more radiological progressions in patients with measurable disease at baseline compared with those without baseline measurable disease. However, even in this latter category, nearly half of the patients experienced first radiological progression. This finding suggests that patients without measurable disease at baseline could be considered for studies that define tumour progression based only on RECIST criteria.

Patients with symptomatic progression were not treated as frequently as those with CA-125 or RECIST progression. It can be speculated that a certain number of patients at the time of symptomatic progression were considered to be unable to receive chemotherapy either because of decreased performance status related to occlusive disease or because of other causes. These findings corroborate with those of the MRC OVAR/EORTC 55955 trial (Rustin et al., 2010). In this trial of women with complete response to first-line chemotherapy, 12% of the patients with symptomatic progression in the delayed-chemotherapy arm could not receive a second-line treatment compared with only 4% of patients randomised to the arm that received chemotherapy as soon as CA-125 progression according to GCIG criteria was observed.

CA-125 measurements and CT-scans performed similarly in comparing efficacy between the two treatment arms in the CALYPSO study. This finding corroborated a previous retrospective report in the first-line chemotherapy setting for advanced ovarian cancer (Rustin et al., 2006). It is important to note that this finding cannot be generalised to all anticancer treatments because some biological therapies could interfere with CA-125 production independent of antitumour effect. On the other hand, some biological agents could delay symptomatic progression in patients with increasing CA-125. Such an effect was recently demonstrated in the CALYPSO experience with CA-125.
Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376: 1155–1163

Rustin GJS, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E (2006) Comparison of CA-125 and standard definitions of progression of ovarian cancer in the Intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24: 45–51

Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gyn 20: 207–225

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216

Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000) Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] Gynecologic Cancer Intergroup. J Natl Cancer Inst 92: 1534–1535

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.